uniQure (NASDAQ:QURE) Expected to Earn Q3 2024 Earnings of ($1.02) Per Share

uniQure (NASDAQ:QURE) – William Blair upped their Q3 2024 earnings per share (EPS) estimates for shares of uniQure in a research report issued to clients and investors on Monday, July 1st. William Blair analyst S. Corwin now anticipates that the biotechnology company will post earnings of ($1.02) per share for the quarter, up from their previous forecast of ($1.18). The consensus estimate for uniQure’s current full-year earnings is ($4.50) per share. William Blair also issued estimates for uniQure’s Q4 2024 earnings at ($1.04) EPS, FY2024 earnings at ($4.56) EPS, Q1 2025 earnings at ($1.04) EPS, Q2 2025 earnings at ($1.05) EPS, Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($0.99) EPS and FY2025 earnings at ($4.06) EPS.

Several other research firms have also weighed in on QURE. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Wednesday, May 8th. Mizuho reduced their price objective on uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

uniQure Price Performance

NASDAQ QURE opened at $3.91 on Thursday. uniQure has a 1-year low of $3.90 and a 1-year high of $11.90. The company has a quick ratio of 9.27, a current ratio of 9.39 and a debt-to-equity ratio of 0.70. The business’s 50-day simple moving average is $4.79 and its 200-day simple moving average is $5.38.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.05). The firm had revenue of $8.49 million during the quarter, compared to analyst estimates of $2.58 million. uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%.

Hedge Funds Weigh In On uniQure

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sectoral Asset Management Inc. acquired a new position in uniQure during the 4th quarter worth approximately $1,981,000. Bridger Management LLC increased its holdings in uniQure by 2,917.3% during the 4th quarter. Bridger Management LLC now owns 362,349 shares of the biotechnology company’s stock worth $2,453,000 after purchasing an additional 350,340 shares during the last quarter. Citigroup Inc. increased its holdings in uniQure by 667.9% during the 3rd quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock worth $5,143,000 after purchasing an additional 666,696 shares during the last quarter. Vontobel Holding Ltd. increased its holdings in uniQure by 458.5% during the 4th quarter. Vontobel Holding Ltd. now owns 295,042 shares of the biotechnology company’s stock worth $1,997,000 after purchasing an additional 242,214 shares during the last quarter. Finally, Hudson Bay Capital Management LP increased its holdings in shares of uniQure by 66.0% in the 3rd quarter. Hudson Bay Capital Management LP now owns 390,200 shares of the biotechnology company’s stock valued at $2,618,000 after acquiring an additional 155,100 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.